REGULATORY
NIBIOHN Strengthens Collaboration with Drug Makers to Promote Development of Japan-Originated Drugs
The National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) will enhance its collaboration with pharma companies in order to promote the development of drugs of Japanese origin. Starting this fiscal year, Hirosato Kondo, who served as head of Shionogi’s…
To read the full story
Related Article
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





